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Background/Aims
Nutrient-induced gut hormone release (eg, cholecystokinin [CCK]) and the modulation of gut motility (particularly pyloric stimulation) 
contribute to the regulation of acute energy intake. Non-caloric bitter compounds, including quinine, have recently been shown 
in cell-line and animal studies to stimulate the release of gastrointestinal hormones by activating bitter taste receptors expressed 
throughout the gastrointestinal tract, and thus, may potentially suppress energy intake without providing additional calories. This 
study aims to evaluate the effects of intraduodenally administered quinine on antropyloroduodenal pressures, plasma CCK and energy 
intake.
Methods
Fourteen healthy, lean men (25 ± 5 years; BMI: 22.5 ± 2.0 kg/m2) received on 4 separate occasions, in randomized, double-blind 
fashion, 60-minute intraduodenal infusions of quinine hydrochloride at doses totaling 37.5 mg (“Q37.5”), 75 mg (“Q75”) or 225 mg 
(“Q225”), or control (all 300 mOsmol). Antropyloroduodenal pressures (high-resolution manometry), plasma CCK (radioimmunoassay), 
and appetite perceptions/gastrointestinal symptoms (visual analog questionnaires) were measured. Ad libitum energy intake 
(buffet-meal) was quantified immediately post-infusion. Oral quinine taste-thresholds were assessed on a separate occasion using 
3-alternative forced-choice procedure.
Results
All participants detected quinine orally (detection-threshold: 0.19 ± 0.07 mmol/L). Intraduodenal quinine did not affect antral, pyloric 
or duodenal pressures, plasma CCK (pmol/L [peak]; control: 3.6 ± 0.4, Q37.5: 3.6 ± 0.4, Q75: 3.7 ± 0.3, Q225: 3.9 ± 0.4), appetite 
perceptions, gastrointestinal symptoms or energy intake (kcal; control: 1088 ± 90, Q37.5: 1057 ± 69, Q75: 1029 ±7 0, Q225: 1077 ± 88).
Conclusion
Quinine, administered intraduodenally over 60 minutes, even at moderately high doses, but low infusion rates, does not modulate 
appetite-related gastrointestinal functions or energy intake.
(J Neurogastroenterol Motil 2019;25:413-422)
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Introduction  
Dietary nutrients are known to potently modulate gastrointes-
tinal (GI) functions, including gut hormones and motor functions 
that underlie the slowing of gastric emptying, resulting in reduc-
tions in energy intake and blood glucose.1-3 There is increasing in-
terest in the effects of bitter compounds to stimulate these GI func-
tions by activating subtypes of the taste 2 receptor (TAS2R) family 
of G protein-coupled receptors expressed on enteroendocrine cells 
throughout the human GI tract,4-7 particularly given the potential to 
suppress energy intake without providing additional calories.
The outcomes of studies in both cell lines and experimental 
animals suggest potent effects of bitter agonists to modulate gut 
hormone release.8-10 For example, denatonium benzoate (DB) and 
phenylthiocarbamide (PTC) have been reported to stimulate cho-
lecystokinin (CCK) secretion from mouse STC-1 cells8 and DB to 
stimulate glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) 
secretion from both human NCI-H716 cells and isolated duodenal 
tissue from mice.10 Moreover, intragastric DB and PTC, but not 
quinine hydrochloride (Q-HCl), stimulate the release of ghrelin 
in mice.9 Interestingly, in the latter study, PTC, but not DB or Q-
HCl, slowed gastric emptying, which was unaffected by adminis-
tration of either the CCK-A receptor antagonist, devazepide, or the 
GLP-1 antagonist, exendin-(9-39).9 Finally, in mice a mixture of 
bitter tastants, including Q-HCl, DB, and PTC, increased food 
intake in the first 30 minutes post-administration, while during the 
subsequent 4 hours there was a marked suppression of food intake.9 
It is, however, important to note that some bitter agonists used in 
these studies (eg, PTC8), at the doses administered, have, in other 
studies, induced strong Ca2+ responses in control cells devoid of 
bitter receptors,11 thus, some of the reported effects may not be spe-
cific to bitter receptor activation.
In humans, studies relating to the effects of bitter agonists on 
gut hormone secretion, GI motility and/or energy intake have yield-
ed inconsistent results and, if any, modest effects.5,6,12,13 Intragastric 
administration of 18 mg Q-HCl in an acid-resistant capsule, had 
no effect on absolute plasma CCK concentrations, while the change 
in plasma CCK relative to baseline was slightly greater 30 minutes 
after consumption of a standardized meal following quinine com-
pared with control,12 and intraduodenal infusion of a higher dose 
(75 mg) did not affect plasma CCK, GLP-1, or PYY.5 Intragastric 
administration of 10 mmol/kg Q-HCl (~250 mg in a 65 kg per-
son) reduced plasma motilin and ghrelin moderately,6 while DB,14 
or intraduodenal Q-HCl,12 had no effect on ghrelin. Intragastric 
administration of DB impaired fundic relaxation4 and decreased an-
tral, but not duodenal, motility,14 while Q-HCl reduced ‘fluctuations 
in antral motility.’6 Finally, intragastric Q-HCl (18 mg) modestly 
reduced energy intake12 and, at the much higher dose of ~250 mg, 
the amount consumed of a palatable chocolate milk shake in healthy 
women,13 while intraduodenal Q-HCl at an intermediate dose (75 
mg) had no effect.5
While these studies provide evidence that some bitter com-
pounds modulate GI functions and energy intake, there are impor-
tant issues which have not been addressed, including the effects of 
quinine across a wide range of doses, the relevance of the location 
of delivery (ie, stomach vs small intestine), and also whether any 
effects on energy intake are related to those on GI hormone and/or 
motor functions. The aim of this study was, therefore, to investigate 
the effects of intraduodenal infusion of a wide range of doses of qui-
nine, given as Q-HCl, on upper GI motor function, gut hormones, 
appetite perceptions, and energy intake. We chose intraduodenal in-
fusion because it allows delivery in a standardized fashion, without 
potential confounding influences from the rate of gastric emptying.
Materials and Methods  
Participants
Fourteen healthy, lean, young men (mean age: 25 ± 5 years; 
body mass index [BMI]: 22.5 ± 2.0 kg/m2) participated in the 
study. Participants were recruited through flyers placed around 
the Royal Adelaide Hospital and local universities, and classified 
advertisements placed in local newspapers. Exclusion criteria were 
smoking, consumption of > 20 g alcohol/day, any medical condi-
tion, surgery, or the use of medications known to affect energy 
intake, appetite, or GI function. All participants were required to be 
weight-stable (< 5% change in body weight) for at least 3 months 
before participation, and unrestrained eaters with a score of  12 on 
the eating-restraint component of the Three-Factor Eating Ques-
tionnaire.15 The Central Adelaide Local Health Network Human 
Research Ethics Committee approved the study protocol (Protocol 
No. HREC/16/RAH/410), and the study was performed in accor-
dance with the Declaration of Helsinki. Each participant provided 
informed, written consent before their inclusion. Once a participant 
was enrolled into the study, they were assigned to a randomized 
treatment order generated by a research officer who was not in-
volved in the data analysis, using an online tool.16 The study was 
registered as a clinical trial with the Australian New Zealand Clini-
cal Trial Registry (Trial No. 12617000719336).17
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Study Outline
The study evaluated the dose-related effects of 60-minute 
intraduodenal infusions of Q-HCl delivering either (1) 37.5 mg 
(“Q37.5”, 0.625 mg/min), (2) 75 mg (“Q75”, 1.25 mg/min) or (3) 
225 mg (“Q225”, 3.75 mg/min), or (4) 0.9% saline (“control”), on 
antropyloroduodenal pressures, plasma CCK, appetite perceptions, 
GI symptoms and energy intake in healthy men (Fig. 1).
Test Solutions
Q-HCl solutions were prepared by dissolving 0.047 g, 0.094 
g or 0.281 g Q-HCl (Sinkona Indonesia Lestari, West Java, Indo-
nesia) and 1.44 g, 1.44 g, or 1.36 g NaCl, respectively, in 150 mL 
distilled water to achieve the required loads. The control solution 
contained 1.45 g NaCl in 150 mL distilled water. All solutions were 
isotonic (300 mOsmol) and administered intraduodenally at a rate 
of 2 mL/min for 60 minutes. The 2 lower doses of Q-HCl (37.5 
mg and 75 mg) were selected based on studies in healthy subjects 
in which 18-75 mg Q-HCl reportedly stimulated CCK secretion,12 
and reduced,12 or had no effect on energy intake.5 The dose of 225 
mg was chosen based on recent reports that Q-HCl at ~250 mg 
reduced the release of both motilin and ghrelin as well as hedonic 
eating moderately.6,13
Study Protocol
Each participant was studied on 4 occasions, separated by 3-10 
days, in a randomized, double-blind fashion. Participants were in-
structed to refrain from vigorous exercise and alcohol consumption 
for 24 hours before each study and were provided with a standard-
ized meal (Beef Lasagne; McCain Food, Wendouree, Victoria, 
Australia; energy content: 602 kcal) to be consumed by 7:00 PM 
on the night before each visit.
On each study day, the participant arrived at the Clinical 
Research Facility at the Adelaide Medical School, University of 
Adelaide, at 8:00 AM after an overnight fast (from food and fluids 
except water after 7:00 PM, and from water after 6:30 AM). On 
arrival, an intravenous cannula was placed in a right forearm vein 
for blood sampling, and the participant was intubated with a small-
diameter (external diameter: 3.5 mm), 17-channel manometric 
catheter (Dentsleeve International, Mui Scientific, Mississauga, 
Ontario, Canada), which was inserted into the stomach through 
an anaesthetized nostril and allowed to pass into the duodenum by 
peristalsis.18 The manometric catheter consisted of 16 side-holes 
spaced at 1.5 cm intervals, measuring pressures in the antrum, 
pylorus, and duodenum.19,20 An additional channel was positioned 
~14.5 cm distal to the pylorus and used for intraduodenal infu-
sion of Q-HCl or control solutions. The correct positioning of 
the catheter was maintained by continuous measurement of the 
transmucosal potential difference between the most distal antral, 
and the most proximal duodenal, channels.21 Once the catheter was 
positioned correctly (within 59 ± 4 minutes across study days and 
participants) and immediately after the occurrence of a phase III 
of the interdigestive migrating motor complex (time from catheter 
insertion to the occurrence of phase III (minutes); control: 67 ± 
7, Q37.5: 72 ± 11, Q75: 84 ± 16, Q225: 76 ± 14, NS), during 
phase I (a period of motor quiescence), a baseline blood sample 
was collected, and the participant completed a visual analogue 
scale (VAS) questionnaire to assess appetite-related perceptions 
(hunger, fullness, desire to eat, prospective food consumption), and 
GI symptoms (nausea, bloating),22 and fasting motility was moni-
tored continuously for 10 minutes (t = –10-0 minutes). At t = 0 
minutes, intraduodenal infusion of either Q-HCl or control com-
menced for 60 minutes. During the infusion, antropyloroduodenal 
pressures were recorded continuously, while blood samples for 
Figure 1. Schematic representation of the study design. At t = –10 
minutes, immediately after the occurrence of a phase III, ie, during 
phase I, with the multi-lumen manometric catheter positioned across 
the pylorus, a baseline blood sample was collected, and the participant 
completed a visual analogue scale (VAS) questionnaire for the as-
sessment of appetite-related perceptions. The recording of pressures 
in the antropyloroduodenal region was also commenced. At t = 0 
minutes, intraduodenal infusion of quinine hydrochloride at 37.5 mg 
(Q37.5), 75 mg (Q75), 225 mg (Q225), or control commenced for 
60 minutes. During the infusion, antropyloroduodenal pressures were 
recorded continuously, and blood samples and VAS ratings were col-
lected at 15-minute intervals. At t = 60 minutes, the intraduodenal 
infusion was terminated, and the catheter removed. The participant 
was then presented with a buffet-style meal and instructed to eat until 
he was comfortably full. At t = 90 minutes, another blood sample was 
collected, and a VAS questionnaire administered, after which the par-
ticipant was free to leave the laboratory.
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measurement of gut hormones and blood glucose were collected, 
and VAS questionnaires completed every 15 minutes. At t = 60 
minutes, the intraduodenal infusion was terminated and the partici-
pant extubated. The participant was then presented with a standard-
ized, cold, buffet-style meal and instructed to consume as much, or 
as little, food as they wished until they felt comfortably full, for up 
to 30 minutes (t = 60-90 minutes).23 The meal comprised 4 slices 
(~120 g) of whole-meal bread, 4 slices (~120 g) of white bread, 
100 g sliced ham, 100 g sliced chicken, 85 g sliced cheddar cheese, 
100 g lettuce, 100 g sliced tomato, 100 g sliced cucumber, 22 g 
mayonnaise, 20 g margarine, 1 apple (~170 g), 1 banana (~190 g), 
175 g strawberry yogurt, 100 g chocolate custard, 120 g fruit salad, 
375 mL iced coffee, 300 mL orange juice, and 600 mL water. The 
buffet meal had a total energy content of ~2300 kcal (~27% fat, 
~52% carbohydrate, and ~21% protein) and weight of ~2924.23 
At t = 90 minutes, after completion of the meal, a final blood sam-
ple was taken, and the VAS completed, and the participant was then 
allowed to leave the laboratory.




Detection thresholds for Q-HCl were determined using the as-
cending series 3-Alternate Forced Choice technique.24 Participants 
were asked to abstain from food, beverages and oral care products 
for at least 2 hours prior to the test, and to prevent confounding 
from non-taste sensory inputs, all tests were conducted while wear-
ing nose clips. Taste samples were prepared by adding Q-HCl at 
varying concentrations (0.00125, 0.0025, 0.0125, 0.025, 0.075, 
0.25, 0.75, 1.5, 3, 7.5, 15, 30, and 75 mmol/L) to distilled water.25 
Control samples consisted of distilled water. Samples were prepared 
fresh on the day of testing. Participants were presented with 3 
samples per set, 2 controls and 1 containing Q-HCl, in ascending 
order from the lowest to the highest concentration. Participants 
rinsed their mouth with distilled water before beginning the task 
and between each sample set. In each set, participants were asked to 
identify the “odd” sample. If incorrect, they were presented with 3 
samples at the next higher concentration and, if correct, with 3 more 
samples at the same concentration. This procedure continued until 
the participant identified the odd sample at a given concentration 3 
consecutive times, and that concentration was defined as their detec-
tion threshold for Q-HCl.
Appetite perceptions, gastrointestinal symptoms, and 
energy intake
Appetite perceptions (including hunger, fullness, desire to eat, 
and prospective food consumption) were quantified with validated 
100-mm VAS questionnaires.22 Nausea and bloating were also as-
sessed. Energy intake (kcal) was calculated from the amount of 
food and liquids (g) consumed at the buffet meal, measured by 
weighing each food item before presentation and at the end of the 
meal, using commercial software (FoodWorks 8.0; Xyris Software, 
Highgate Hill, Queensland, Australia).23
Antropyloroduodenal motility
Antropyloroduodenal pressures were digitized and recorded 
using a computer-based system running commercially available 
software (Solar GI, MMS Data base software, version 8.17; Medi-
cal Measurement Systems BV, Enschede, The Netherlands), and 
stored for subsequent analysis. The number and amplitude of an-
tral, isolated pyloric, and duodenal pressure waves, as well as basal 
pyloric pressure, using custom-written software modified to our 
requirements (kindly provided by Professor Emeritus A Smout, 
University Medical Centre, Amsterdam, The Netherlands), as de-
scribed previously.26
Plasma cholecystokinin and blood glucose  
concentrations
Blood samples were collected into ice-chilled ethylenediamine-
tetraacetic acid-coated tubes. Plasma was separated by centrifuga-
Table 1. Energy Content and Amount of Food and Liquids Consumed at the Buffet Meal Immediately After 60-minute Intraduodenal Infusions 
of Quinine Hydrochloride or Control
Parameter C Q37.5 Q75 Q225 P-value
Energy intake (kcal) 1088 ± 90 1057 ± 69 1029 ± 70 1077 ± 88 NS
Amount consumed (g) 1157 ± 90 1161 ± 84 1113 ± 76 1144 ± 98 NS
C, saline control; Q37.5, quinine hydrochloride load of 37.5 mg; Q75, quinine hydrochloride load of 75 mg; Q225, quinine hydrochloride load of 225 mg; NS, non-
significant. 
Data are means ± SEMs (n = 14). 
P-values for main treatment effects were determined by one-way ANOVA.
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Figure 2. Scores for hunger (A), desire to eat (B), prospective food consumption (C), fullness (D), bloating (E), and nausea (F) during 60-minute 
intraduodenal infusions (t = 0-60 minutes) of quinine hydrochloride at 37.5 mg (Q37.5), 75 mg (Q75), 225 mg (Q225), or control, and after the 
buffet meal, at t = 90 minutes. Two-way ANOVAs, with treatment and time as factors, were used to assess differences between treatments. Post-
hoc comparisons, adjusted for multiple comparisons by Bonferroni’s correction, were used to determine significant differences between either dose 
or control. Comparisons of post (t = 90 minutes) vs pre-meal (t = 60 minutes) data were done with Student’s paired t test. Data are expressed as 
means ± SEMs; n = 14. ID, intraduodenal.
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tion at ~1830 g for 15 minutes at 4°C within 15 minutes of collec-
tion and stored at –70℃ until assayed.
Plasma CCK-8 concentrations (pmol/L) were measured by ra-
dioimmunoassay after ethanol extraction using an adaptation of the 
method of Santangelo et al.27 Intra- and inter-assay coefficients of 
variation were ~9.2% and 13.7%, respectively. The detection limit 
was 1 pmol/L.
Blood glucose was determined with a portable glucometer 
(Medisense Precision QLD; Abbott Laboratories, North Ryde, 
New South Wales, Australia), and was quantified because of the 
potential of quinine to cause hypoglycaemia.
Statistical Methods
The number of participants was determined by power calcula-
tions based on our previous work.28 We calculated that with 14 
participants, we would be able to detect a 15% decrease in energy 
intake at α = 0.05, with a power of 80%.
Baseline values for all data were calculated as means of values 
obtained between t = –10 and t = 0 minutes. For antral, isolated 
pyloric, and duodenal pressure waves, total numbers, and mean 
amplitudes were calculated over the 60-minute infusion period. 
Number and amplitude of antral and duodenal pressure waves were 
used to calculate motility indices (MI) using the following equa-
tion: MI (mmHg∙number) = natural logarithm {[sum of ampli-
tudes × number of contractions (pressure waves)] + 1}.29 Basal 
pyloric pressures were averaged over the 60-minute infusion period. 
Plasma CCK and blood glucose concentrations were measured in 
duplicate and expressed as means at each time point.
Statistical analyses were performed with SPSS software (version 
24.0; IBM Corp, Somers, NY, USA). VAS scores, plasma CCK 
and blood glucose concentrations were analyzed using repeated-
measures 2-way ANOVA, with treatment (Q37.5, Q75, Q225, and 
control) and time (0-60 minutes) as factors. Sphericity of the time 
effect for all models was evaluated by Mauchly’s test and, when vio-
lated, the adjusted Greenhouse-Geisser P-value was reported. Mo-
tility data, energy intake and amount of food and liquids consumed 
from the test meal were analyzed using one-way ANOVA. Post-hoc 
comparisons, adjusted for multiple comparisons by Bonferroni’s 
correction, were performed where ANOVAs revealed significant 
effects. Comparisons of post-meal (t = 90 minutes) vs pre-meal (t 
= 60 minutes) CCK and glucose concentrations were done using 
Student’s paired t test. All data are reported as means ± SEMs. 
All tests were 2-tailed, and differences were considered statistically 
significant at P < 0.05.
Results  
All subjects completed all 4 study visits and tolerated the ex-
perimental procedures well, and detected Q-HCl orally (detection-
threshold: 0.19 ± 0.07 mmol/L).
Energy Intake
There was no effect of treatment on energy intake (kcal) or the 
amount consumed (g) from the buffet meal (Table 1).
Table 2. Number, Amplitude, and Motility Index of Antral and Duodenal Pressure Waves, Basal Pyloric Pressure, and Number and Amplitude 
of Isolated Pyloric Pressure Waves During 60-minute Intraduodenal Infusions of Quinine Hydrochloride or Control
Parameter C Q37.5 Q75 Q225 P-value
Antral pressure waves
    Number 39 ± 13 27 ± 11 37 ± 12 29 ± 13 NS
    Amplitude (mmHg) 29 ± 6 21 ± 7 30 ± 5 43 ± 11 NS
    Motility index (mmHg·min) 8 ± 1 6 ± 1 9 ± 1 7 ± 1 NS
Basal pyloric pressure (mmHg) 1 ± 1 –2 ± 1 0 ± 0 –1 ± 1 NS
Isolated pyloric pressure waves
    Number 21 ± 5 15 ± 3 22 ± 6 16 ± 4 NS
    Amplitude (mmHg) 76 ± 9 73 ± 16 59 ± 8 51 ± 10 NS
Duodenal pressure waves
    Number 253 ± 31 266 ± 52 248 ± 32 235 ± 46 NS
    Amplitude (mmHg) 26 ± 1 28 ± 2 24 ± 2 25 ± 1 NS
    Motility index (mmHg·min) 14 ± 0 14 ± 0 14 ± 0 14 ± 0 NS
C, saline control; Q37.5, quinine hydrochloride load of 37.5 mg; Q75, quinine hydrochloride load of 75 mg; Q225, quinine hydrochloride load of 225 mg; NS, non-
significant. 
Data are means ± SEMs (n = 14). 
P-values for main treatment effects were determined by one-way ANOVA.
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Appetite Perceptions and Gastrointestinal 
Symptoms
There were no differences in baseline ratings, or any effect of 
treatment or time, on ratings of hunger, desire to eat, prospective 
food consumption, fullness, nausea, or bloating (Fig. 2A-F).
Antropyloroduodenal Pressures
Baseline values for antral, pyloric or duodenal pressures did 
not differ between study days, and there was no effect of treatment 
on the total number, mean amplitude, or MI, of antral or duodenal 
pressures, basal pyloric pressure or the number or amplitude of iso-
lated pyloric pressure waves (Table 2).
Plasma Cholecystokinin Concentrations
There were no differences in baseline plasma CCK concentra-
tions between study days, and no effect of treatment on plasma 
CCK. Plasma CCK increased substantially in response to the buffet 
meal with all treatments (time effect: P < 0.05), with no difference 
between treatments (Fig. 3A).
Blood Glucose Concentrations
There were no differences in baseline values for blood glucose 
between study days, and no effect of treatment on blood glucose. In 
response to the buffet meal, blood glucose increased with all treat-
ments (time effect: P < 0.05), with no difference between treat-
ments (Fig. 3B).
Discussion  
Our study indicates that slow intraduodenal administration 
of quinine over 60 minutes, at the loads used, does not affect the 
acute antropyloroduodenal motility, plasma CCK or energy intake 
responses to quinine, and, therefore, at least under these conditions, 
does not appear to be a potent stimulus for small-intestinal bitter 
taste receptors to modulate appetite-related GI functions and energy 
intake.
There has been much interest in characterising the effects of 
bitter compounds on gut hormone release,8-10,12 since (1) bitter taste 
receptors are expressed on enteroendocrine cells in the GI lumen, 
(2) gut hormones, including CCK, GLP-1, and PYY, mediate the 
effects of nutrients on GI motor function and gastric emptying, and 
(3) gut hormones play a critical role in the regulation of appetite and 
energy intake.3,30 Results from studies in humans have, however, 
been inconsistent, and effects, if any, appear to be modest.5,6,12-14 We 
were particularly interested in the effect of quinine on CCK, given 
the findings in preclinical studies of potent CCK release by other 
bitter substances8 and our previous work in humans demonstrating 
potent release of CCK by dietary nutrients, associated with marked 
suppression of energy intake.19,28 In line with the previous studies 
in humans on the effects of quinine on plasma CCK levels,5,12 we 
found no effect of even the highest dose of intraduodenal quinine on 
plasma CCK concentrations. Thus, our data suggest that Q-HCl, 
administered at a slow rate, is not a potent stimulus for enteroendo-
crine cells that release CCK.
Previous studies on the effects of bitter compounds on GI mo-
Figure 3. Plasma cholecystokinin (A) and blood glucose (B) concentrations during 60-minute intraduodenal infusions (t = 0-60 minutes) of 
quinine hydrochloride at 37.5 mg (Q37.5), 75 mg (Q75), 225 mg (Q225), or control, and after the buffet meal, at t = 90 minutes. Data were ana-
lyzed using 2-way ANOVA, with treatment and time as factors. Comparison of post (t = 90 minutes) vs pre-meal (t = 60 minutes) concentrations 
were done with Student’s paired t test. Data are expressed as means ± SEMs; n = 14. ID, intraduodenal.
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tor functions have yielded diverse, and inconsistent, outcomes. For 
example, in mouse gastric tissue, DB and chloroquine stimulated, 
while PTC inhibited, antral contractility.4 Moreover, in mice, in-
tragastric gavage of PTC, but not DB or Q-HCl, slowed gastric 
emptying.9 In humans, intragastric administration of DB has 
been reported to impair nutrient-induced fundic relaxation4 and 
decrease antral, but not duodenal, motility, but to have no effect on 
gastric emptying of a solid meal.14 Intragastric administration of 
~250 mg reduced ‘fluctuations in antral motility.’6 We found that 
intraduodenal infusion of Q-HCl, using a wide range of doses that 
spanned those used in previous studies of the effects of quinine on 
gut hormone release, motility, and energy intake,5,6,12 had no effect 
on antral, pyloric or duodenal pressures, suggesting that quinine, 
when administered intraduodenally at a slow rate, at the loads used, 
does not modulate antropyloroduodenal motility in humans. Since 
CCK potently modulates upper GI motor function,31-33 the absence 
of CCK release in the current study likely explains the lack of effect 
of Q-HCl on antropyloroduodenal pressures.
In line with the lack of effect of Q-HCl to modulate upper 
GI motility, particularly pyloric pressures, or stimulate CCK, both 
of which we have identified as key determinants of the subsequent 
suppression of energy intake in response to duodenal nutrients,1,34 
we found no effect of Q-HCl to reduce appetite or energy intake. 
In a recent study, DB reduced hunger ratings in the fasting state, 
and decreased hunger and increased satiety after a meal, but did 
not significantly reduce caloric intake from a standardized meal, 
with substantial variability between individuals.14 Moreover, while 
intragastric administration of 18 mg Q-HCl reduced energy intake 
in one study12 and, at a much higher dose (~250 mg), modestly 
reduced the amount consumed of a palatable milk shake in healthy 
females,13 intraduodenal infusion of 75 mg Q-HCl was ineffective.5 
Thus, overall findings are mixed, and more studies are warranted 
to determine the conditions under which bitter substances, includ-
ing Q-HCl, stimulate GI functions that underlie the regulation of 
energy intake, and suppress energy intake.
A key issue with the existing research on the effects of bitter 
compounds on GI function and energy intake is the substantial 
variation in outcomes between studies, which is potentially at-
tributable to a number of factors. These include variations in the 
bitter compounds used and the doses applied, administration of the 
compounds to cell models vs into the stomach or small intestine 
of humans or animals, and using either bolus administration or 
slower infusions over time.4-6,8,10,12-14 There are currently 25 known 
subtypes of TAS2Rs in humans,35 and different bitter agonists 
activate different combinations of receptor subtypes, for example, 
quinine activates 9 subtypes of TAS2Rs, including TAS2R4, 7, 10, 
14, 39, 40, 43, 44, and 46, and DB activates 8 subtypes, including 
TAS2R4, 8, 10, 13, 39, 43, 46, and 47.35 The difference in the sub-
types of TAS2Rs that are activated by each bitter compound,35 as 
well as species differences in TAS2Rs,11 are likely to explain some of 
the differences in observed effects. Stimulation of the release of gut 
hormones by bitter compounds depends on the presence of specific 
bitter receptor subtypes on enteroendocrine cells; evidence of the 
identity, and functions, of some subtypes on enteroendocrine cells 
is emerging. For example, a recent study in humans reported that 
TAS2R38s are expressed on human colonic enteroendocrine cells 
and are colocalized with immunoreactivity for CCK, GLP-1 or 
PYY.36 Interestingly, neither quinine nor DB activate the TAS2R38 
subtype.35 The regional distribution of bitter receptor subtypes 
across the stomach, small and large intestines may also vary.37 Thus, 
much more research is required to better understand the roles and 
functions of the various bitter receptor subtypes in humans, as well 
as their specific activation by particular bitter compounds. Inter-
individual variations in bitter taste perception that have been docu-
mented for oral taste38 may also exist in the gut and, thus, influence 
the responses to intraluminal bitter compounds. Finally, the GI 
responses to bitter substances may be influenced by the habitual 
diet, in analogy to fat,39 with evidence of an inverse relationship 
between intake of bitter vegetables and the ability to taste the bit-
ter substance, 6-n-propylthiouracil in children;40 furthermore, the 
ability to taste bitter may also be modified by dietary energy and fat 
consumption.41,42
Some potential limitations of our study should be recognized. 
We only studied males, as they have been shown to be more sensi-
tive to dietary manipulations,43 while, in contrast, it has been re-
ported recently14 that females appear to be more sensitive to bitter 
taste, however, all our volunteers readily detected Q-HCl. Our 
study evaluated the effects of intraduodenal, rather than intragas-
tric or oral, Q-HCl administration, thus, studies are warranted to 
elucidate the relative contributions of gastric and oral perception of 
bitter taste to the regulation of GI functions and appetite. We only 
analyzed the effects on plasma CCK concentrations, and not other 
gut hormones, including GLP-1, PYY, or ghrelin, but given that 
we found no effects on GI motility or energy intake, we believe that 
any effects on other hormones would be unlikely.
In conclusion, our study establishes that intraduodenal admin-
istration of Q-HCl, over a wide range of doses, when infused over 
a 60-minute period, does not affect antropyloroduodenal pressures, 
plasma CCK or energy intake. Further studies are warranted that 
evaluate conditions under which quinine may stimulate bitter recep-
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tors to modulate appetite-related GI functions and energy intake, 
including the effects of varying concentrations of quinine, and the 
relative effects of oral, intragastric and intraduodenal administra-
tion.
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